Biotech Intellectual Property at the Crossroads

Category: Super Sessions
Date/Time: Monday, May 18, 2009, 2:00PM - 3:30PM
Location: Georgia World Congress Center
Sponsor(s): Eli Lilly & Company
Registration Site: http://convention.bio.org/

The U.S. biotechnology industry today faces a confluence of legislative, judicial, and executive branch developments that will profoundly affect its business model for decades to come.  Biotechnology, as an industry singularly dependant on its intellectual property assets, must consider the impact of the biggest proposed changes to the patent laws in over 50 years.
In addition, Congress is poised to create an abbreviated FDA regulatory pathway for follow-on biologics while, at the same time, attempting to establish a framework that will fairly protect the intellectual property, including patents and clinical trial data, developed by biotechnology innovators.  In this session, experts will identify key policy issues at the intersection of intellectual property and healthcare, and apply lessons learned from 25 years of generic drug regulation to explore the role of patents, clinical data protection provisions, and other policy tools to ensure continued incentives for biotechnology innovation.

Chairs

• John Lechleiter
  Chairman, President & Chief Executive Officer
  Eli Lilly & Company

Speakers

• Gregory Glover
  Partner, Life Sciences Practice
  Ropes & Gray, LLP
• Robert Armitage
  Senior VP & General Counsel
  Eli Lilly & Company
• H. Thomas Watkins
  President & CEO
  Human Genome Sciences, Inc

Add Session to myBIO